Respiratory Syncytial Virus Infections
Conditions
Keywords
Respiratory syncytial virus (RSV), Vaccine, Safety, Reactogenicity, Immunogenicity
Brief summary
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years. As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted in 2 parts (Part A and Part B).
Interventions
BIOLOGICALRSV Vaccine (GSK3844766A) unadjuvanted low dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
BIOLOGICALRSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
BIOLOGICALRSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
BIOLOGICALRSV Vaccine (GSK3844766A) unadjuvanted medium dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
BIOLOGICALRSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
BIOLOGICALRSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
BIOLOGICALRSV Vaccine (GSK3844766A) unadjuvanted high dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
BIOLOGICALRSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
BIOLOGICALRSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
For all subjects: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject prior to performing any study specific procedure. For Part A: • A male or female between, and including, 18 and 40 years of age at the time of the first vaccination. For Part B: * A male or female between, and including, 60 and 80 years of age at the time of the first vaccination. * Subjects with residence status allowing free mixing with general community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living.
Exclusion criteria
For all subjects: * Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period. * Any medical condition that in the judgment of the investigator would make IM injection unsafe. * Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone (≥ 20 mg/day, or equivalent). Inhaled and topical steroids are allowed. * Administration of long-acting immune-modifying drugs or planned administration at any time during the study period. * Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 30 days after each study vaccination. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * Hypersensitivity to latex. * Serious or unstable chronic illness. Patients with chronic stable conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study. * Any other condition (e.g. chronic obstructive pulmonary disease or severe respiratory condition) that, in the opinion of the investigator, might interfere with the evaluations required by the study. * History of any neurological disorders or seizures. * Acute disease and/or fever at the time of enrolment. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by the investigator based on medical history, physical examination or laboratory screening tests. * Hepatomegaly, right upper quadrant abdominal pain or tenderness. * Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccine or planned administration during the study period. * History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study. * Previous vaccination with an RSV vaccine. * Lymphoproliferative disorder and malignancy within 5 years. * Body mass index \> 40 kg/m². * Planned move to a location that will prohibit participating in the trial until study end. * At screening: Hematology parameters (complete blood cell count \[red blood cells, white blood cells\], white blood cells differential count \[lymphocytes, neutrophils and eosinophils\], platelets count or hemoglobin level) and/or biochemistry parameters (creatinine, blood urea nitrogen or liver enzymes \[alanine aminotransferase or aspartate aminotransferase\]) outside the normal laboratory ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator. For Part A: * Pregnant or lactating female. * Female subjects of childbearing potential, except if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. For Part B: * Known previous administration of a vaccine containing MPL, QS-21 and/or MF59 (e.g. GSK Biologicals' vaccine against human papillomavirus infection marketed as Cervarix, GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix, an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine \[HZ/su\], or MF59 adjuvanted influenza vaccines \[e.g. Fluad\]). * Planned administration of GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix or an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine \[HZ/su\] within 180 days after the second dose of the study vaccine. * Bedridden subjects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | From first vaccination (Day 1) up to 30 days post second vaccination (Day 91) | pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. |
| Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | At baseline and at 7 days after the first vaccine dose (Day 8) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges. |
| Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | At baseline and at 7 days after the second vaccine dose (Day 68) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges. |
| Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | At baseline and at 7 days after the second vaccine dose (Day 68) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges. |
| Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first dose of vaccination | A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy. |
| Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second dose of vaccination | A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy. |
| Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | From first vaccination (Day 1) up to 30 days post second vaccination (Day 91) | A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. |
| Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | During a 7-day follow-up period after first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days) | Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm) |
| Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | During a 7-day follow-up period after second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days) | Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm) |
| Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | During a 7-day follow-up period after the first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days) | Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering. |
| Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | During a 7-day follow-up period after the second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days) | Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination dose (across doses) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | At baseline and at 7 days after the first vaccine dose (Day 8) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | From Day 1 up to the end of follow-up period (Month 14) | pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. |
| Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | During the RSV season (from October 2019 to March 2020) | The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab). |
| Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91) | Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60). |
| Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91) | The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL). |
| Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91) | Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range. |
| Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | From Day 1 up to the end of follow-up period (Month 14) | A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. |
Countries
Belgium, United States
Participant flow
Pre-assignment details
1053 participants received the study vaccine or placebo and were included in the Exposed Set.
Participants by arm
| Arm | Count |
|---|---|
| Low Dose_PLAIN_A Group Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 12 |
| Medium Dose_PLAIN_A Group Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 12 |
| High Dose_PLAIN_A Group Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 12 |
| Placebo_A Group Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (Saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 12 |
| Low Dose_PLAIN_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 101 |
| Medium Dose_PLAIN_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 97 |
| High Dose_PLAIN_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 100 |
| Low Dose_AS01E_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 101 |
| Medium Dose_AS01E_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 101 |
| High Dose_AS01E_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 100 |
| Low Dose_AS01B_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 103 |
| Medium Dose_AS01B_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 100 |
| High Dose_AS01B_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 101 |
| Placebo_B Group Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (Saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm. | 101 |
| Total | 1,053 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 0 |
| Overall Study | CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | 3 | 1 | 0 | 1 | 2 |
| Overall Study | Lost to Follow-up | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Overall Study | MIGRATED / MOVED FROM THE STUDY AREA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | UNKNOWN REASON | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 31.2 Years STANDARD_DEVIATION 7 | 26.5 Years STANDARD_DEVIATION 4 | 29.9 Years STANDARD_DEVIATION 6.1 | 31.6 Years STANDARD_DEVIATION 5.6 | 67.3 Years STANDARD_DEVIATION 5.6 | 67.8 Years STANDARD_DEVIATION 5.6 | 67.9 Years STANDARD_DEVIATION 4.9 | 67.8 Years STANDARD_DEVIATION 5.1 | 67.1 Years STANDARD_DEVIATION 5.6 | 67.6 Years STANDARD_DEVIATION 5.2 | 67.6 Years STANDARD_DEVIATION 4.9 | 67.5 Years STANDARD_DEVIATION 4.9 | 67.5 Years STANDARD_DEVIATION 4.9 | 68.1 Years STANDARD_DEVIATION 5.7 | 65.9 Years STANDARD_DEVIATION 9.5 |
| Race/Ethnicity, Customized AMERICAN INDIAN OR ALASKA NATIVE | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized ASIAN | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized BLACK OR AFRICAN AMERICAN | 2 Participants | 1 Participants | 2 Participants | 1 Participants | 5 Participants | 7 Participants | 4 Participants | 12 Participants | 7 Participants | 5 Participants | 11 Participants | 7 Participants | 7 Participants | 4 Participants | 75 Participants |
| Race/Ethnicity, Customized OTHER | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized WHITE | 10 Participants | 10 Participants | 10 Participants | 11 Participants | 95 Participants | 90 Participants | 93 Participants | 88 Participants | 94 Participants | 93 Participants | 92 Participants | 93 Participants | 92 Participants | 97 Participants | 968 Participants |
| Sex: Female, Male Female | 8 Participants | 7 Participants | 7 Participants | 9 Participants | 58 Participants | 54 Participants | 57 Participants | 58 Participants | 57 Participants | 57 Participants | 59 Participants | 58 Participants | 57 Participants | 58 Participants | 604 Participants |
| Sex: Female, Male Male | 4 Participants | 5 Participants | 5 Participants | 3 Participants | 43 Participants | 43 Participants | 43 Participants | 43 Participants | 44 Participants | 43 Participants | 44 Participants | 42 Participants | 44 Participants | 43 Participants | 449 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 101 | 1 / 97 | 1 / 100 | 0 / 101 | 0 / 101 | 0 / 100 | 1 / 103 | 0 / 100 | 1 / 101 | 0 / 101 |
| other Total, other adverse events | 9 / 12 | 10 / 12 | 9 / 12 | 10 / 12 | 62 / 101 | 54 / 97 | 61 / 100 | 77 / 101 | 80 / 101 | 83 / 100 | 91 / 103 | 88 / 100 | 93 / 101 | 54 / 101 |
| serious Total, serious adverse events | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 12 | 13 / 101 | 3 / 97 | 5 / 100 | 8 / 101 | 6 / 101 | 11 / 100 | 9 / 103 | 5 / 100 | 9 / 101 | 9 / 101 |
Outcome results
Primary
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part A groups, with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophis-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 8 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 8 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 11 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 11 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophis-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 11 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 11 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 12 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 9 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophis-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophis-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
Primary
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part B groups, with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 96 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 98 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 100 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 99 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 85 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 5 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 5 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 91 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 4 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 99 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 4 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 87 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 97 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 94 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 100 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 94 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 4 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 9 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 5 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 97 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 96 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 4 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 86 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 83 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 5 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 92 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 96 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 97 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 83 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 99 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 99 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 94 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 88 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 98 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 91 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 98 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 94 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 95 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 91 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 87 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 4 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 4 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 97 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 92 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 93 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 98 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 94 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 99 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 97 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 91 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 89 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 98 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 93 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 89 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 96 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 89 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 88 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 7 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 90 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 88 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 98 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 99 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 98 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 6 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 90 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 97 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 98 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 90 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 87 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 100 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 93 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 93 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 98 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 5 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 93 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 88 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 90 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 88 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 5 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 98 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 100 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 88 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 97 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 4 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 97 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 103 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 93 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 94 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 97 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 100 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 5 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 88 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 96 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 92 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 5 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 4 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 98 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 90 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 91 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 96 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 86 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 96 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 4 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 90 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 96 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 88 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 98 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 98 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 96 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 86 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 93 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 100 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 90 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 96 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 93 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 98 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 101 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 93 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 95 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 95 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 93 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 89 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 90 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 100 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 96 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 5 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 98 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 5 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 95 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 94 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 95 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 98 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 90 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 99 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Basophils-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 98 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 6 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups) | Monocytes-WITHIN-ABOVE | 0 Participants |
Primary
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part A groups, with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 9 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 10 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 7 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 10 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 12 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-UNKNOWN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 10 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 11 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-UNKNOWN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 9 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 7 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 9 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-ABOVE | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 10 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 8 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 8 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 9 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 11 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 10 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | AST-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Urea Nitrogen-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Eosinophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Uric Acid-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-WITHIN-WITHIN | 10 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Creatinine-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-WITHIN-WITHIN | 12 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Monocytes-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Basophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-WITHIN-WITHIN | 11 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Lymphocytes-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | White Blood Cells-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups) | Hemoglobin-WITHIN-WITHIN | 12 Participants |
Primary
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part B groups, with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 82 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 7 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 94 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 93 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 87 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 5 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 83 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 81 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 83 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 6 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 95 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 90 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 91 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 86 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 4 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 88 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 86 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 81 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 92 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 4 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 89 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 85 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 92 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 93 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 6 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 83 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 88 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 90 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 86 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 91 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 87 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 90 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 78 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 94 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 87 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 93 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 88 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 91 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 86 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 90 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 91 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 89 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 96 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 87 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 4 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 92 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 79 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 90 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 6 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 93 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 93 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 2 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 6 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 91 Participants |
| Placebo_A Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 86 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 97 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 86 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 88 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 94 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 79 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 90 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 91 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 88 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 95 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 92 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 83 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 2 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 98 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 95 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 91 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 88 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 88 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 92 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 90 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 5 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 82 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 83 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 82 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 6 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 6 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 90 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 94 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 83 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 92 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 88 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 89 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 95 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 91 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 4 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 4 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 6 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 78 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 91 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 6 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 87 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 88 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 91 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 4 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 92 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 96 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 91 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 87 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 91 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 90 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 94 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 86 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 93 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 7 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 95 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 83 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 94 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 88 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 96 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 91 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 90 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 92 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 6 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 90 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 83 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 89 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 89 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 89 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 8 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 82 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 88 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 91 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 94 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 95 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 89 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 91 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 83 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-WITHIN | 83 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-WITHIN | 96 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-ABOVE | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-WITHIN | 90 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-WITHIN | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-WITHIN | 91 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-BELOW-BELOW | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-BELOW-BELOW | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-WITHIN | 97 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-WITHIN | 97 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-UNKNOWN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-BELOW-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-WITHIN | 91 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-ABOVE | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Urea Nitrogen-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Uric Acid-WITHIN-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | White Blood Cells-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Lymphocytes-WITHIN-BELOW | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-UNKNOWN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-WITHIN | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-UNKNOWN-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-WITHIN | 92 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-BELOW-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Neutrophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-WITHIN | 87 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-WITHIN | 88 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-WITHIN | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-UNKNOWN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-BELOW-WITHIN | 5 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-WITHIN | 96 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Platelets-BELOW-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Eosinophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-BELOW | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-WITHIN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-BELOW-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Creatinine-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Basophils-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-WITHIN | 91 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-WITHIN | 97 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | ALT-ABOVE-ABOVE | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-ABOVE-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-BELOW-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Monocytes-UNKNOWN-WITHIN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-BELOW-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-ABOVE | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | AST-UNKNOWN-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-ABOVE-WITHIN | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-WITHIN | 92 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-BELOW | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-WITHIN-ABOVE | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Hemoglobin-UNKNOWN-BELOW | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-WITHIN-UNKNOWN | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups) | Erythrocytes-BELOW-BELOW | 1 Participants |
Primary
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first dose of vaccination
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 4 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 2 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 7 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 5 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 1 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 6 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 2 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 7 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 3 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 3 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 6 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 8 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 4 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 4 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | Any adverse event | 4 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination | General adverse event | 4 Participants |
Primary
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second dose of vaccination
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 4 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 1 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 5 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 3 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 4 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 8 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 5 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 2 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 5 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 7 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 3 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 1 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 2 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Local adverse event | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | Any adverse event | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination | General adverse event | 0 Participants |
Primary
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part B groups with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 Participants |
Primary
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 6 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 4 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 2 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 1 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 1 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 3 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 5 Participants |
| Placebo_B Group | Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 1 Participants |
Primary
Number of Subjects With Any Solicited General Symptom After First Vaccination Dose
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
Time frame: During a 7-day follow-up period after the first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented and with the subject diary completed after the first vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 4 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 4 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 5 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 1 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 2 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 1 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 1 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 6 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 8 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 22 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 7 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 4 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 8 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 7 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 11 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 3 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 8 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 10 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 24 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 13 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 8 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 7 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 26 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 9 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 6 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 1 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 20 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 8 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 12 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 28 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 12 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 8 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 21 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 6 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 9 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 6 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 17 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 3 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 28 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 15 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 19 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 13 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 30 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 3 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 12 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 7 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 29 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 9 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 12 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 27 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 3 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 8 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 1 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 13 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 16 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 49 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 18 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 17 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 28 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Shivering | 1 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Gastrointestinal symptoms | 10 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fatigue | 16 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Headache | 8 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Arthralgia | 7 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Fever | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After First Vaccination Dose | Myalgia | 5 Participants |
Primary
Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
Time frame: During a 7-day follow-up period after the second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented and with the subject diary completed after the second vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 2 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 3 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 2 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 5 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 3 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 2 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 16 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 11 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 9 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 11 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 2 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 4 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 3 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 7 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 8 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 13 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 9 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 6 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 8 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 15 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 24 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 7 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 22 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 8 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 18 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 9 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 11 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 24 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 4 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 10 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 7 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 1 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 10 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 11 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 33 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 4 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 14 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 19 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 21 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 35 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 11 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 12 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 26 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 7 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 6 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 12 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 35 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 9 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 9 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 3 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 13 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 18 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 34 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 18 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fatigue | 16 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Fever | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Gastrointestinal symptoms | 6 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Shivering | 2 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Myalgia | 2 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Headache | 9 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose | Arthralgia | 4 Participants |
Primary
Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
Time frame: During a 7-day follow-up period after first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented and with the subject diary completed after the first vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 7 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 1 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 6 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 9 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 5 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 14 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 5 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 54 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 7 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 6 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 57 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 7 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 9 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 56 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 6 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 10 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 16 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 78 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 63 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 15 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 7 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 18 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 76 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 9 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Swelling | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Pain | 4 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose | Erythema | 1 Participants |
Primary
Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
Time frame: During a 7-day follow-up period after second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented and with the subject diary completed after the second vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 5 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 7 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 8 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 1 Participants |
| Placebo_A Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 1 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 18 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 18 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 23 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 2 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 3 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 34 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 3 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 48 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 47 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 6 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 7 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 58 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 10 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 16 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 14 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 7 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 56 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 10 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 59 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 12 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Swelling | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Erythema | 0 Participants |
| Placebo_B Group | Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose | Pain | 4 Participants |
Primary
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination dose (across doses)
Population: The analysis was performed on the Exposed Set that includes all subjects with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 4 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 4 Participants |
| Placebo_A Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 6 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 34 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 28 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 30 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 40 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 29 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 36 Participants |
| Low Dose_AS01B_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 39 Participants |
| Medium Dose_AS01B_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 34 Participants |
| High Dose_AS01B_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 43 Participants |
| Placebo_B Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 33 Participants |
Secondary
Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers
Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range.
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Population: The analysis was performed on the PPS that includes all subjects who receive at least 1 dose of the study treatment to which they are randomized and have post-vaccination data, minus subjects with protocol deviations that lead to exclusion.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1271.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 400.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1649.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1006.5 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 2302.5 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1515.0 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1221.0 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 272.0 Cells per million CD4+ T Cells |
| High Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 317.5 Cells per million CD4+ T Cells |
| High Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1487.0 Cells per million CD4+ T Cells |
| High Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1773.5 Cells per million CD4+ T Cells |
| High Dose_PLAIN_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1066.0 Cells per million CD4+ T Cells |
| Placebo_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 393.0 Cells per million CD4+ T Cells |
| Placebo_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 303.0 Cells per million CD4+ T Cells |
| Placebo_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 374.5 Cells per million CD4+ T Cells |
| Placebo_A Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 263.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 888.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 208.5 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 688.0 Cells per million CD4+ T Cells |
| Low Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 979.5 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 166.0 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1089.5 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1034.0 Cells per million CD4+ T Cells |
| Medium Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 737.0 Cells per million CD4+ T Cells |
| High Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 770.0 Cells per million CD4+ T Cells |
| High Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 225.5 Cells per million CD4+ T Cells |
| High Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1052.0 Cells per million CD4+ T Cells |
| High Dose_PLAIN_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1081.5 Cells per million CD4+ T Cells |
| Low Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1086.0 Cells per million CD4+ T Cells |
| Low Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 209.5 Cells per million CD4+ T Cells |
| Low Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1594.0 Cells per million CD4+ T Cells |
| Low Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1732.0 Cells per million CD4+ T Cells |
| Medium Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1020.0 Cells per million CD4+ T Cells |
| Medium Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1603.5 Cells per million CD4+ T Cells |
| Medium Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 188.0 Cells per million CD4+ T Cells |
| Medium Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1297.0 Cells per million CD4+ T Cells |
| High Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1496.0 Cells per million CD4+ T Cells |
| High Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 934.0 Cells per million CD4+ T Cells |
| High Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1466.0 Cells per million CD4+ T Cells |
| High Dose_AS01E_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 192.0 Cells per million CD4+ T Cells |
| Low Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1952.0 Cells per million CD4+ T Cells |
| Low Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1966.0 Cells per million CD4+ T Cells |
| Low Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1228.5 Cells per million CD4+ T Cells |
| Low Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 187.5 Cells per million CD4+ T Cells |
| Medium Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1315.0 Cells per million CD4+ T Cells |
| Medium Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1690.5 Cells per million CD4+ T Cells |
| Medium Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 1558.0 Cells per million CD4+ T Cells |
| Medium Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 185.0 Cells per million CD4+ T Cells |
| High Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 2096.5 Cells per million CD4+ T Cells |
| High Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 206.0 Cells per million CD4+ T Cells |
| High Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 1742.5 Cells per million CD4+ T Cells |
| High Dose_AS01B_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 1078.0 Cells per million CD4+ T Cells |
| Placebo_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 31 | 176.0 Cells per million CD4+ T Cells |
| Placebo_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 61 | 183.0 Cells per million CD4+ T Cells |
| Placebo_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 1 | 178.0 Cells per million CD4+ T Cells |
| Placebo_B Group | Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers | Day 91 | 190.5 Cells per million CD4+ T Cells |
Secondary
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A
Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Population: The analysis was performed on the Per Protocol Set (PPS) that includes all subjects who receive the study treatment to which they are randomized and have post-vaccination data, minus subjects with protocol deviations that lead to exclusion.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 7658.4 Titers |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 6237.8 Titers |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 4659.8 Titers |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 1019 Titers |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 5895.8 Titers |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 846.2 Titers |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 5457.5 Titers |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 11741.8 Titers |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 8136.9 Titers |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 4761.5 Titers |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 3651 Titers |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 673.6 Titers |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 787.9 Titers |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 586.5 Titers |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 620.7 Titers |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 789.1 Titers |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 1015.5 Titers |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 3936.2 Titers |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 5657.9 Titers |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 5422.6 Titers |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 1146.5 Titers |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 5632.1 Titers |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 7371 Titers |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 6490.8 Titers |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 976.7 Titers |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 9403.1 Titers |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 7907.4 Titers |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 5956.1 Titers |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 5258.5 Titers |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 5019.4 Titers |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 960.9 Titers |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 3924.7 Titers |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 4770 Titers |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 6509.4 Titers |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 6201.9 Titers |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 966.4 Titers |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 961.9 Titers |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 5175.5 Titers |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 6681.7 Titers |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 9350.9 Titers |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 4435.9 Titers |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 6026.1 Titers |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 5048.9 Titers |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 981.6 Titers |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 4850.5 Titers |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 5902.1 Titers |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 6899.5 Titers |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 1023 Titers |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 1035.7 Titers |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 7201.4 Titers |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 8527.7 Titers |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 5980.6 Titers |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 61 | 903.4 Titers |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 1 | 837.4 Titers |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 31 | 751.7 Titers |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A | Day 91 | 772.4 Titers |
Secondary
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Population: The analysis was performed on the PPS that includes all subjects who receive at least 1 dose of the study treatment to which they are randomized and have post-vaccination data, minus subjects with protocol deviations that lead to exclusion.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 50590.1 ELU/mL |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 69843.3 ELU/mL |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 54900 ELU/mL |
| Low Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 8330.7 ELU/mL |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 54884.7 ELU/mL |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 58980.8 ELU/mL |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 97848.5 ELU/mL |
| Medium Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7699.5 ELU/mL |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 56380.6 ELU/mL |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7439.1 ELU/mL |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 96645.4 ELU/mL |
| High Dose_PLAIN_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 55444.4 ELU/mL |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 6524.8 ELU/mL |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 6246 ELU/mL |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 6601 ELU/mL |
| Placebo_A Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 6242.4 ELU/mL |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 42523.7 ELU/mL |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 53994 ELU/mL |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 47594.2 ELU/mL |
| Low Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7500.2 ELU/mL |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 56855.4 ELU/mL |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7209.7 ELU/mL |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 54711.2 ELU/mL |
| Medium Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 71618.4 ELU/mL |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 70294.1 ELU/mL |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 60955.2 ELU/mL |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 90933.2 ELU/mL |
| High Dose_PLAIN_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7134.9 ELU/mL |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 41543.8 ELU/mL |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 6760.5 ELU/mL |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 53598.9 ELU/mL |
| Low Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 42504.6 ELU/mL |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 51209.9 ELU/mL |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 52846.4 ELU/mL |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7438 ELU/mL |
| Medium Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 63823.4 ELU/mL |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 6685.4 ELU/mL |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 59624.5 ELU/mL |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 83462.5 ELU/mL |
| High Dose_AS01E_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 62543.2 ELU/mL |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 45679.1 ELU/mL |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 53779.9 ELU/mL |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 59026.1 ELU/mL |
| Low Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7468.5 ELU/mL |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 70524 ELU/mL |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 57314.9 ELU/mL |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 54342.7 ELU/mL |
| Medium Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 7245.5 ELU/mL |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 78831.2 ELU/mL |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 61577.7 ELU/mL |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 6655.4 ELU/mL |
| High Dose_AS01B_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 61433.7 ELU/mL |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 1 | 6543.8 ELU/mL |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 61 | 6307.9 ELU/mL |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 31 | 6593.4 ELU/mL |
| Placebo_B Group | Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations | Day 91 | 6748.7 ELU/mL |
Secondary
Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part B groups with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 1 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| Placebo_A Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 1 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 1 Participants |
| High Dose_PLAIN_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 0 Participants |
| High Dose_AS01E_B Group | Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 1 Participants |
Secondary
Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Population: The analysis was performed on the Exposed Set that includes all subjects from Part B with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 13 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 3 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 5 Participants |
| Placebo_A Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 8 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 6 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 11 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 9 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 5 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 9 Participants |
| High Dose_AS01E_B Group | Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 9 Participants |
Secondary
Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups
The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab).
Time frame: During the RSV season (from October 2019 to March 2020)
Population: The analysis was performed on the Exposed Set that includes all subjects from part B groups with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 1 Participants |
| Low Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 19 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 2 Participants |
| Medium Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 12 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| High Dose_PLAIN_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 20 Participants |
| Placebo_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| Placebo_A Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 14 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 17 Participants |
| Low Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 22 Participants |
| Medium Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 20 Participants |
| High Dose_PLAIN_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 2 Participants |
| Low Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 16 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 0 Participants |
| Medium Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 13 Participants |
| High Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV+ | 3 Participants |
| High Dose_AS01E_B Group | Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups | RSV- | 11 Participants |